Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset
by Zacks Equity Research
Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.
Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
by Zacks Equity Research
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
Top Stock Reports for Pfizer, Union Pacific & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Union Pacific (UNP) and Broadcom (AVGO).
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive
by Zacks Equity Research
AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.
Bristol-Myers (BMY) Reports Data from CheckMate-214 Study
by Zacks Equity Research
Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.
Kitov (KTOV) Gets Approval from FDA for Consensi, Shares Up
by Zacks Equity Research
Kitov Pharma (KTOV) gained as the FDA approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.
Pfizer's Xalkori Gets Breakthrough Status for New Indications
by Zacks Equity Research
Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications.
Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval
by Swarup Gupta
The Dow endured another volatile week marked by key geopolitical developments.
Novartis Gets Approval for Remicade Biosimilar in Europe
by Zacks Equity Research
Novartis' (NVS) Sandoz wins approval for a biosimilar version of Remicade in Europe, which should further strengthen its biosimilars portfolio.
Pfizer's Tafamadis Gets Breakthrough Therapy Designation
by Zacks Equity Research
Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
by Zacks Equity Research
Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
by Zacks Equity Research
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
by Zacks Equity Research
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Dow 30 Stock Roundup: Walmart, Cisco, Home Depot Beat on Earnings
by Swarup Gupta
The Dow snapped a record streak of wins to traverse a turbulent week.
Roche Tecentriq Combo Achieves Longer Overall Survival Rate
by Zacks Equity Research
Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.
Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
by Zacks Equity Research
European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.
Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
by Zacks Equity Research
Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.
Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y
by Zacks Equity Research
Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.
Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks?
by Ritujay Ghosh
Stocks of pharmaceutical companies get a boost as Trump's proposal will actually not directly hamper their profitability.
Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?
by Zacks Equity Research
Both Merck and Pfizer reported upbeat first-quarter results on May 1
Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline
by Zacks Equity Research
Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, U.S. Bancorp, Tesla and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, U.S. Bancorp, Tesla and Celgene